Why is "3,4-Diaminopyridine" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-13 11:08:17
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Amifampridine phosphate is used as a drug, predominantly in the treatment of a number of rare muscle diseases. The free base form of the drug has been used to treat congenital myasthenic syndromes and approved by the FDA for Lambert–Eaton myasthenic syndrome (LEMS) through compassionate use programs since the 1990s and was recommended as a first line treatment for LEMS in 2006, using ad hoc forms of the drug, since there was no marketed form.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Chatting with a pillar of the community about life with LEMS - Lambert-Eaton News
-
Amifampridine in LEMS and Beyond: Unraveling Its Therapeutic Potential - NeurologyLive
-
Family outraged over life-changing treatment going from free to $375,000 a year - NBC News
-
Free Myasthenic Syndrome Drug Program Threatened in Race for FDA Approval - Neurology Today
-
Slow-Channel Congenital Myasthenic Syndrome Due to the Novel Variant c.1396G_A in CHRNA1 That Responds Favorably to 3,4-Diaminopyridine: A Case Report - Cureus
-
Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies - The Lancet
-
Safety, efficacy and steroid-sparing effect of amifampridine in Lambert-Eaton myasthenic syndrome patients — real world data | Szczudlik | Neurologia i Neurochirurgia Polska - Via Medica Journals
-
3,4-Diaminopyridine in the Treatment of Lambert–Eaton Myasthenic Syndrome - NEJM
-
Myasthenia Gravis Patients Benefit from LEMS Treatment Firdapse, Study Finds - Myasthenia Gravis News
-
Aminopyridines for the treatment of neurologic disorders - Neurology® Journals
-
Structure-activity relationship studies of four novel 4-aminopyridine K+ channel blockers | Scientific Reports - Nature
-
Managing Myasthenia Gravis During the COVID-19 Pandemic - Brain & Life
-
Catalyst plays the R&D card to defend Firdapse’s $375K sticker against Bernie Sanders' ire - Fierce Pharma
-
Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome - Cureus
-
FDA Approves a Second Orphan Drug for LEMS. Then It Is Promptly Sued by a Rival Drug's Maker - Neurology Today
-
Chemical and biophysical characterization of novel potassium channel blocker 3-fluoro-5-methylpyridin-4-amine - Nature
-
Effect of chlorzoxazone in patients with downbeat nystagmus - Neurology® Journals
-
Safety, efficacy and steroid-sparing effect of amifampridine in Lambert-Eaton myasthenic syndrome patients — real world data | Szczudlik | Neurologia i Neurochirurgia Polska - Via Medica Journals
-
Channels Inhibit Parasympathetic Ganglion Transmission and Vagal Control of Heart Rate in Hypertensive Rats - Frontiers
-
Use-dependent potentiation of voltage-gated calcium channels rescues neurotransmission in nerve terminals intoxicated by botulinum neurotoxin serotype A - Nature
-
Bernie Sanders asks why Catalyst Pharmaceutical is pricing a once-free drug at $375,000 - Burlington Free Press
-
FDA Approval Could Turn A Free Drug For A Rare Disease Pricey - 90.5 WESA
-
Presynaptic Deficits at Neuromuscular Junctions: A Specific Cause and Potential Target of Axonal Neuropathy in Type 2 Charcot–Marie–Tooth Disease - Journal of Neuroscience
-
Clinical Reasoning: A child with arthrogryposis - Neurology® Journals
-
4-aminopyridine reverses ataxia and cerebellar firing deficiency in a mouse model of spinocerebellar ataxia type 6 - Nature
-
Neuromuscular blocking effect of fluoxetine and its interaction with rocuronium - Wiley Online Library
-
Synergistic effect of tartaric acid with 2,6-diaminopyridine on the corrosion inhibition of mild steel in 0.5 M HCl - Nature
-
Catalyst Pharmaceutical Partners Provides Update on FIRDAPSE(TM) Progress - GlobeNewswire
-
Trials and treatments developed with our support - AFM Téléthon
-
In vitro cytotoxicity activity of novel Schiff base ligand–lanthanide complexes - Nature
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.